Skip to content
Top Globe News – Lifestyle
Author:
Immutep Limited
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
July 13, 2026
Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
June 4, 2026
Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
May 28, 2026
Immutep Receives Nasdaq Notice of Bid Price Deficiency
April 30, 2026
Immutep Quarterly Activities Report Q3 FY26
April 30, 2026
←
Previous Page
1
2